Search results
Showing 166 to 180 of 1070 results for drug therapy
Bortezomib monotherapy for relapsed multiple myeloma (TA129)
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)
Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.
Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.